Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
Abstract This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhe...
Guardado en:
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5eb65bd70e574ceb9712c6801b7e4352 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:5eb65bd70e574ceb9712c6801b7e4352 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:5eb65bd70e574ceb9712c6801b7e43522021-12-02T13:39:34ZRuxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia10.1038/s41598-021-88080-32045-2322https://doaj.org/article/5eb65bd70e574ceb9712c6801b7e43522021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88080-3https://doaj.org/toc/2045-2322Abstract This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou University from July 2017 to October 2019. They were divided into control(16 patients) and ruxolitinib (41 patients) groups. For aGVHD prophylaxis, the control group received post-transplantation cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil, while in the ruxolitinib group, ruxolitinib 5 mg/d in adults or 0.07–0.1 mg/(kg d) in children was administered from the day of neutrophil engraftment to 100 days post-transplantation based on control group. We found 55 patients had successful reconstitution of hematopoiesis; No significant difference was found in cGVHD, hemorrhagic cystitis, pulmonary infection, intestinal infection, Epstein-Barr virus infection, cytomegalovirus infection, relapse, death, and nonrelapse mortality. The incidences of aGVHD (50 vs. 22%, P = 0.046) and grade II–IV aGVHD (42.9 vs. 12.2%, P = 0.013) were significantly higher in the control group than in the ruxolitinib group. No significant differences were observed in overall survival (P = 0.514), disease-free survival (P = 0.691), and cumulative platelet transfusion within 100 days post-transplantation between two groups. This suggests early application of ruxolitinib can reduce the incidence and severity of aGVHD and patients are well tolerated.Binglei ZhangLingyun ChenJian ZhouYingling ZuRuirui GuiZhen LiJuan WangFengkuan YuYanli ZhangHuifang ZhaoZhenyu JiYongping SongNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Binglei Zhang Lingyun Chen Jian Zhou Yingling Zu Ruirui Gui Zhen Li Juan Wang Fengkuan Yu Yanli Zhang Huifang Zhao Zhenyu Ji Yongping Song Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
description |
Abstract This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou University from July 2017 to October 2019. They were divided into control(16 patients) and ruxolitinib (41 patients) groups. For aGVHD prophylaxis, the control group received post-transplantation cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil, while in the ruxolitinib group, ruxolitinib 5 mg/d in adults or 0.07–0.1 mg/(kg d) in children was administered from the day of neutrophil engraftment to 100 days post-transplantation based on control group. We found 55 patients had successful reconstitution of hematopoiesis; No significant difference was found in cGVHD, hemorrhagic cystitis, pulmonary infection, intestinal infection, Epstein-Barr virus infection, cytomegalovirus infection, relapse, death, and nonrelapse mortality. The incidences of aGVHD (50 vs. 22%, P = 0.046) and grade II–IV aGVHD (42.9 vs. 12.2%, P = 0.013) were significantly higher in the control group than in the ruxolitinib group. No significant differences were observed in overall survival (P = 0.514), disease-free survival (P = 0.691), and cumulative platelet transfusion within 100 days post-transplantation between two groups. This suggests early application of ruxolitinib can reduce the incidence and severity of aGVHD and patients are well tolerated. |
format |
article |
author |
Binglei Zhang Lingyun Chen Jian Zhou Yingling Zu Ruirui Gui Zhen Li Juan Wang Fengkuan Yu Yanli Zhang Huifang Zhao Zhenyu Ji Yongping Song |
author_facet |
Binglei Zhang Lingyun Chen Jian Zhou Yingling Zu Ruirui Gui Zhen Li Juan Wang Fengkuan Yu Yanli Zhang Huifang Zhao Zhenyu Ji Yongping Song |
author_sort |
Binglei Zhang |
title |
Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_short |
Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_full |
Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_fullStr |
Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_full_unstemmed |
Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_sort |
ruxolitinib early administration reduces acute gvhd after alternative donor hematopoietic stem cell transplantation in acute leukemia |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/5eb65bd70e574ceb9712c6801b7e4352 |
work_keys_str_mv |
AT bingleizhang ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT lingyunchen ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT jianzhou ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT yinglingzu ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT ruiruigui ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT zhenli ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT juanwang ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT fengkuanyu ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT yanlizhang ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT huifangzhao ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT zhenyuji ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT yongpingsong ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia |
_version_ |
1718392617373270016 |